Treatment patterns and deep molecular response in chronic phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study

References

• Jabbour EJ, Cortes JE, Kantarjian HM. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013;13:1433–1452.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006;81:973–988.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Strom SS, O’Brien S. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186–e193.
   PubMed Web of Science ®Google Scholar
• Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. ASH Educ. Program Book. 2009;2009:461–476.
   Google Scholar
• Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. ASH Educ Program Book. 2009;2009:477–487.
   Google Scholar
• Abruzzese E, Breccia M, Latagliata R. Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML). BioDrugs. 2014;28:17–26.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Khoury HJ, Kantarjian HM, et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol. 2016;91:1206–1214.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study. Haematologica. 2018;103:1298.
   PubMedGoogle Scholar
• Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22:1200–1206.
   PubMed Web of Science ®Google Scholar
• Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27:107–112.
   PubMed Web of Science ®Google Scholar
• Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123:2317–2324.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486–3492.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141–1145.
   PubMed Web of Science ®Google Scholar
• Etienne G, Dulucq S, Nicolini F-E, et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica. 2014;99:458–464.
   PubMed Web of Science ®Google Scholar
• Falchi L, Kantarjian HM, Wang X, et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013;88:1024. 10.1002/ajh.23560.
   PubMed Web of Science ®Google Scholar
• Patel AB, Wilds BW, Deininger MW. Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop? Expert Rev Hematol. 2017;10:659–674.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Cortes JE. Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia. J Clin Oncol. 2014;32:3077.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2014;20:310–322.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv41–iv51.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic Myeloid Leuk. 2018;4:2018.
   Google Scholar
• Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525–1531.
   PubMed Web of Science ®Google Scholar
• Mahon F-X, Boquimpani C, Takahashi N, et al. Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results. J Clin Oncol. 2018;36:7003–7003.
   Web of Science ®Google Scholar
• Pal SK, Signorovitch JE, Li N, et al. Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA. Int J Urol. 2017;24:272–278.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
   Web of Science ®Google Scholar
• Griffin JD, Guerin A, Chen L, et al. Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib - a retrospective chart review analysis. Curr Med Res Opin. 2013;29:623–631.
   PubMed Web of Science ®Google Scholar
• Li N, Yang X, Fan L, et al. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data. J Med Econ. 2017;20:328–336.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–2259.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333–2340.
   PubMed Web of Science ®Google Scholar
• Dulucq S, Mahon FX. Deep molecular responses for treatment-free remission in chronic myeloid leukemia. Cancer Med. 2016;5:2398–2411.
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32:415–423.
   PubMed Web of Science ®Google Scholar
• Saußele S, Richter J, Hochhaus A, et al. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638–1647.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes J, Guilhot F, et al. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer. 2007;109:1365–1375.
   PubMed Web of Science ®Google Scholar
• Cortes J, De Souza C, Ayala-Sanchez M, et al. Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). Cancer. 2010;116:4991–5000.
   PubMed Web of Science ®Google Scholar
• Mendizabal AM, Garcia-Gonzalez P, Levine PH. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol. 2013;37:247–254.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Hochhaus A, Kantarjian HM, et al. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 2014;99:1204–1211.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Munhoz E, Aurelio Salvino M, et al. Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. Br J Haematol. 2017;179:219–228.
   PubMed Web of Science ®Google Scholar
• Gora-Tybor J, Medras E, Calbecka M, et al. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. Leuk Lymphoma. 2015;56:2309–2314.
   PubMed Web of Science ®Google Scholar
• Ghorab A, Kantarjian HM, Elhalawani H, et al. Comparative risk assessment of imatinib, nilotinib and dasatinib in randomized controlled trials: a meta-analysis. Blood. 2017;130:2869–2869.
   Web of Science ®Google Scholar